Developer docs
API playgroundTry for free, no card

Search company profiles

Doppl

Full company profile

uuid0003fio

Namestring
Doppl
Legal namestring
Doppl SA
Websiteurl
doppl.ch
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Doppl SA is a Lausanne, Switzerland-based organoid technology company founded in 2022 that engineers standardized 3D cell-based organoid models for disease modeling and personalized medicine. At the core of its offering is the Bio-base, a crowd-sourced database of biological samples contributed by citizen donors who retain control over their data, paired with the Gri3D organoid platform technology (a registered trademark) and the Bionoid test applied in cystic fibrosis and other rare disease research. The company ran three primary service lines: Compound Profiling (toxicity screening using human healthy gastro-intestinal organoids), Epithelial Fluid Transport screening, and Model Development (customized organoid lines for client-specified tissues or diseases), with applications spanning oncology, immuno-oncology, inflammatory diseases, ADME-Tox, and rare disease therapeutics.

Short descriptiontext

Doppl SA is a Lausanne-based organoid technology company founded in 2022 that engineers standardized 3D cell-based disease models and runs a crowd-sourced citizen-donor Bio-base, serving pharmaceutical, biotech, and academic clients in preclinical drug development and personalized medicine research.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLausanne, Switzerland
HQ citystring
Lausanne
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organoid technology, preclinical drug development, disease modeling services, personalized medicine research, toxicity screening services
Industry3 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Drug Development Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Organoid Model Development Services
TypeProfessional Services
Description

Custom organoid lines developed to accurately model specific tissues or diseases of interest for pharmaceutical clients. Revenue generated through project-based service contracts with biotech and pharma companies.

doppl.ch
2Compound Profiling Services
TypeProfessional Services
Description

Toxicity screening services using established models of human healthy gastro-intestinal organoids for preclinical drug development.

doppl.ch
3Epithelial Fluid Transport Screening
TypeProfessional Services
Description

Screening services for epithelial fluid transport using human healthy gastro-intestinal organoid models.

doppl.ch
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1B2B enterprise pricing for organoid services
ModelOtherBilling cadenceMulti-year contract
Notes

Services are quoted individually based on client requirements. No public pricing tiers available.

doppl.ch
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Doppl engineers industry-standard human organoids and organs-on-chip models for disease modeling and personalized medicine, engaging in partnered preclinical drug development projects for pharmaceutical and biotech clients. The company delivers three core services—compound toxicity profiling, epithelial fluid transport screening, and customized organoid line development—backed by the Bio-base crowd-sourced database of biological samples contributed by citizen donors who retain control over their data.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Expanded Bionoid test validation from 1 to 11 cystic fibrosis patients
Product overview1 text field

Doppl SA is a company specializing in engineering industry-standard organoids for disease modeling and personalized medicine. The company operates the Bio-base, a crowd-sourced database of biological samples that enables research and drug development. Doppl offers three core services: Compound Profiling (toxicity screening), Epithelial Fluid Transport screening, and Model Development (customized organoid lines). The company also developed the Bionoid Test for precision medicine applications. The portfolio spans applications in oncology, inflammatory diseases, rare diseases (including cystic fibrosis), immuno-oncology, and ADME-Tox testing.

Product and service5 records
1Compound Profiling
CategoryPreclinical Screening Service
Description

Toxicity screening service using an established model of human healthy gastro-intestinal organoids to assess compound safety profiles for pharmaceutical and biotech preclinical drug development clients.

2Epithelial Fluid Transport
CategoryPreclinical Screening Service
Description

Screening service for epithelial fluid transport using established models of human healthy gastro-intestinal organoids, supporting preclinical drug development and translational research for pharmaceutical clients.

3Model Development
CategoryCustom Organoid Development Service
Description

Customized organoid line development service that accurately models specific tissues or diseases of interest, built to client specifications for preclinical research and drug development programs.

4Bio-base
CategoryBiological Sample Database Platform
Description

A global, crowd-sourced database of biological samples used to power critical research and drug development. Citizen donors contribute biological data while retaining control over their samples, supporting personalized medicine initiatives and supplying material for Doppl's organoid services.

5Bionoid Test
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

EPFL serves as a key research and innovation partner, hosting Doppl's headquarters in the EPFL Innovation Building L. The partnership provides access to academic research capabilities and facilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CHUV is a university hospital partner collaborating with Doppl on clinical research and organoid applications. The partnership enables hospital-laboratory collaboration for personalized medicine research.

Strategic tierSupportingTypeTechnology or Integration
Description

Laboratory instrumentation partner providing automation and liquid handling solutions that integrate with Doppl's organoid production workflows.

Strategic tierSupportingTypeTechnology or Integration
Description

Life sciences reagent partner providing biological assays and reagents for Doppl's screening and profiling services.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Online research services marketplace that connects pharma and biotech companies with research service providers including Doppl.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

InSphero AG acquired DOPPL SA including the Gri3D technology in November 2025, representing a significant strategic transition where Doppl's technology became integrated into InSphero's 3D cell model offerings for pharmaceutical R&D.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Doppl

Preclinical Drug Development Servicesdoppl.ch

Doppl SA is a Lausanne-based organoid technology company founded in 2022 that engineers standardized 3D cell-based disease models and runs a crowd-sourced citizen-donor Bio-base, serving pharmaceutical, biotech, and academic clients in preclinical drug development and personalized medicine research.

What Doppl does

Doppl SA is a Lausanne, Switzerland-based organoid technology company founded in 2022 that engineers standardized 3D cell-based organoid models for disease modeling and personalized medicine. At the core of its offering is the Bio-base, a crowd-sourced database of biological samples contributed by citizen donors who retain control over their data, paired with the Gri3D organoid platform technology (a registered trademark) and the Bionoid test applied in cystic fibrosis and other rare disease research. The company ran three primary service lines: Compound Profiling (toxicity screening using human healthy gastro-intestinal organoids), Epithelial Fluid Transport screening, and Model Development (customized organoid lines for client-specified tissues or diseases), with applications spanning oncology, immuno-oncology, inflammatory diseases, ADME-Tox, and rare disease therapeutics.

Doppl firmographics

Firmographics
Name
Doppl
Legal name
Doppl SA
Website
https://doppl.ch
Company type
Private
Founded year
2022
Operating status
Acquired
Headcount range
11–50 employees
Short description
Doppl SA is a Lausanne-based organoid technology company founded in 2022 that engineers standardized 3D cell-based disease models and runs a crowd-sourced citizen-donor Bio-base, serving pharmaceutical, biotech, and academic clients in preclinical drug development and personalized medicine research.
Ownership category
akta.pro rank

Doppl industry classification

Industry
Product category
Preclinical Drug Development Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Organoid technology
  • Preclinical drug development
  • Disease modeling services
  • Personalized medicine research
  • Toxicity screening services

Where Doppl is headquartered

Location

Headquarters

HQ city
Lausanne
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Doppl business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Organoid Model Development Services: Custom organoid lines developed to accurately model specific tissues or diseases of interest for pharmaceutical clients. Revenue generated through project-based service contracts with biotech and pharma companies.
  2. Compound Profiling Services: Toxicity screening services using established models of human healthy gastro-intestinal organoids for preclinical drug development.
  3. Epithelial Fluid Transport Screening: Screening services for epithelial fluid transport using human healthy gastro-intestinal organoid models.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B enterprise pricing for organoid services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Doppl product offering

Product offering

Core offering

Doppl engineers industry-standard human organoids and organs-on-chip models for disease modeling and personalized medicine, engaging in partnered preclinical drug development projects for pharmaceutical and biotech clients. The company delivers three core services—compound toxicity profiling, epithelial fluid transport screening, and customized organoid line development—backed by the Bio-base crowd-sourced database of biological samples contributed by citizen donors who retain control over their data.

Product overview

Doppl SA is a company specializing in engineering industry-standard organoids for disease modeling and personalized medicine. The company operates the Bio-base, a crowd-sourced database of biological samples that enables research and drug development. Doppl offers three core services: Compound Profiling (toxicity screening), Epithelial Fluid Transport screening, and Model Development (customized organoid lines). The company also developed the Bionoid Test for precision medicine applications. The portfolio spans applications in oncology, inflammatory diseases, rare diseases (including cystic fibrosis), immuno-oncology, and ADME-Tox testing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Compound Profiling Toxicity screening service using an established model of human healthy gastro-intestinal organoids to assess compound safety profiles for pharmaceutical and biotech preclinical drug development clients.
  • Epithelial Fluid Transport Screening service for epithelial fluid transport using established models of human healthy gastro-intestinal organoids, supporting preclinical drug development and translational research for pharmaceutical clients.
  • Model Development Customized organoid line development service that accurately models specific tissues or diseases of interest, built to client specifications for preclinical research and drug development programs.
  • Bio-base A global, crowd-sourced database of biological samples used to power critical research and drug development. Citizen donors contribute biological data while retaining control over their samples, supporting personalized medicine initiatives and supplying material for Doppl's organoid services.
  • Bionoid Test

Quantifiable outcome

  • Expanded Bionoid test validation from 1 to 11 cystic fibrosis patients

Companies that use Doppl

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Doppl technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Doppl partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and supporting.

  • EPFL (École Polytechnique Fédérale de Lausanne)coreStrategic or Co-development PartnerEPFL serves as a key research and innovation partner, hosting Doppl's headquarters in the EPFL Innovation Building L. The partnership provides access to academic research capabilities and facilities.
  • CHUV (Centre Hospitalier Universitaire Vaudois)coreStrategic or Co-development PartnerCHUV is a university hospital partner collaborating with Doppl on clinical research and organoid applications. The partnership enables hospital-laboratory collaboration for personalized medicine research.
  • TecansupportingTechnology or IntegrationLaboratory instrumentation partner providing automation and liquid handling solutions that integrate with Doppl's organoid production workflows.
  • PromegasupportingTechnology or IntegrationLife sciences reagent partner providing biological assays and reagents for Doppl's screening and profiling services.
  • Scientist.comsupportingChannel Partner/ Reseller/ DistributorOnline research services marketplace that connects pharma and biotech companies with research service providers including Doppl.
  • InSphero AGcoreOEM/ Whitelabel/ Licensing PartnerInSphero AG acquired DOPPL SA including the Gri3D technology in November 2025, representing a significant strategic transition where Doppl's technology became integrated into InSphero's 3D cell model offerings for pharmaceutical R&D.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Doppl competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Doppl social profiles

Digital presence

Doppl financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Doppl leadership team

Management profile

Number of profiles

Profiles12 records

Doppl funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Doppl M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Doppl

What does Doppl do?

Doppl engineers industry-standard human organoids and organs-on-chip models for disease modeling and personalized medicine, engaging in partnered preclinical drug development projects for pharmaceutical and biotech clients. The company delivers three core services—compound toxicity profiling, epithelial fluid transport screening, and customized organoid line development—backed by the Bio-base crowd-sourced database of biological samples contributed by citizen donors who retain control over their data.

Is Doppl a public or private company?

Doppl is a private company. It is classified as corporate owned and is currently acquired.

When was Doppl founded?

Doppl was founded in 2022. It employs 11 to 50 people.

Where is Doppl based?

Doppl is headquartered in Lausanne, Switzerland, in the Europe region.

How does Doppl make money?

Three revenue lines are on record. Organoid Model Development Services are the primary driver. The others are compound Profiling Services and epithelial Fluid Transport Screening.

Does Doppl have an API?

No public API is recorded for Doppl.

What industry is Doppl in?

Doppl's product category is Preclinical Drug Development Services. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireInSphero Launches 3D InSight™ DIGIT Platform for Early Gastrointestinal Toxicity AssessmentInSphero launched the 3D InSight™ DIGIT platform for early gastrointestinal toxicity assessment, combining DOPPL's patient-derived intestinal organoids with its standardized screening model. The platform delivers decision-ready IC₅₀ values and functional readouts, available immediately through monthly batch campaigns.BioAlpsInSphero acquires DOPPL SA and Sun Bioscience Gri3D TechnologyInSphero AG, a global market leader in 3D cell-based assays and organ-on-chip systems, signed a definitive agreement to acquire DOPPL SA, a Lausanne-based innovator in organoid technology including Sun Bioscience's Gri3D® platform. The acquisition combines scalable spheroid and organoid technologies, enabling InSphero to offer a unified 3D model ecosystem from standardized spheroids to complex organoids for pharmaceutical research and drug discovery. This strategic move positions InSphero to better serve pharmaceutical, biotechnology, and academic customers seeking human-relevant 3D in vitro models to replace animal testing.EIN PresswireInSphero Expands 3D Cell Model Leadership with Acquisition of DOPPL SA and Sun Bioscience Gri3D TechnologyInSphero AG, a Swiss 3D cell-based assay company, signed a definitive agreement to acquire DOPPL SA, a Lausanne-based organoid innovator, along with the Sun Bioscience Gri3D® technology platform. The acquisition combines scalable spheroid technologies with Sun Bioscience's organoid culture platform and DOPPL's assay development expertise to create a unified 3D model ecosystem for pharmaceutical R&D and drug discovery. The move positions InSphero as a comprehensive provider offering the full spectrum of 3D in vitro models, from standardized spheroids to complex patient-derived organoids, under one roof.startupticker.chInSphero acquires DOPPL SA and Sun Bioscience Gri3D TechnologyInSphero AG, a global market leader in 3D cell-based assays and organ-on-chip systems, has signed a definitive agreement to acquire DOPPL SA and Sun Bioscience's Gri3D technology. The acquisition combines InSphero's scalable spheroid technology with Sun Bioscience's Gri3D organoid culture platform and DOPPL's expertise in organoid assay development, creating what the company calls the most comprehensive 3D in vitro model offering. The deal aims to provide pharmaceutical, biotech, and academic customers with a unified ecosystem spanning from standardized spheroids to patient-derived organoid models for drug discovery and safety testing.startupticker.chDOPPL and Rea Diagnostics get FIT Funding BoostThe Foundation for Technological Innovation (FIT) awarded a CHF 500,000 Tech Growth loan to DOPPL and a CHF 100,000 Tech Seed loan to Rea Diagnostics. The funding will support DOPPL's regulatory certification and team expansion for its organoid engineering platform, while enabling Rea Diagnostics to conduct clinical trials for its premature birth detection technology.startupticker.chDOPPL citizen-led precision medicine gets FIT supportDOPPL, a citizen-led precision medicine startup, secured financing from the Foundation for Technological Innovation (FIT) to expand its Cystic Fibrosis proof points from one to eleven patients. The company utilizes its crowd-sourced biobank and Bionoid test to validate personalized treatments, having previously demonstrated efficacy with a patient in January 2022. This funding supports efforts to convince CHUV to adopt the Bionoid test for all Cystic Fibrosis patients and aids co-founders Sylke Hoehnel and Nathalie Brandenberg in raising CHF 15 million.